GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy

European Journal of Heart Failure

Volumn 4, Issue 2, 2002, Pages 185-191

  Imazio, M ^a   Bobbio, M ^a   Broglio, F ^a   Benso, A ^a   Podio, V ^a   Valetto, M R ^a   Bisi, G ^a   Ghigo, E ^a   Trevi, G P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Dilated cardiomyopathy; Growth hormone; Growth hormone secretagogues; Hexarelin; Ischemic cardiomyopathy

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CARVEDILOL; ENALAPRIL; FUROSEMIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; INOTROPIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEART CONTRACTION; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SCINTIANGIOGRAPHY;

ADULT; CARDIOMYOPATHY, DILATED; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OLIGOPEPTIDES; SEVERITY OF ILLNESS INDEX; STATISTICS; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036120015     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00223-9     Document Type: Article

References (45)

1. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
2. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
3. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of the therapy in V-IIeFT II
4. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
5. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
6. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
7. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
8. Body composition, bone metabolism, heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
9. Growth hormone improves cardiac performance in experimental heart failure
10. Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental heart failure
11. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle
12. Reversible dilated cardiomyopathy due to growth hormone deficiency
13. Cardiac failure responding to growth hormone
14. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy
15. Hemodynamic effects of intravenous growth hormone in congestive heart failure
16. Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
17. A placebo controlled study of growth hormone in patients with congestive heart failure
18. Growth hormone resistance in chronic heart failure
19. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
20. Growth hormone-releasing peptides and their analogs
21. Growth hormone-releasing peptides and the cardiovascular system
22. GHRP receptors in pituitary, central nervous system and peripheral human tissues
23. Presence of specific receptors for synthetic growth hormone secretagogues in the human heart
24. 2 in young adult men and women
25. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues
26. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin and thyroxine levels in beales
27. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man
28. Arginine enhances the growth hormone (GH)-releasing activity, of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration
29. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging
30. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects
31. The growth hormone response to Hexarelin in children: Reproducibility, and effect of sex steroids
32. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome
33. Intranasal administration of the GHRP Hexarelin accelerates growth in short children
34. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness
35. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone deficient rats: Protection by hexarelin
36. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency
37. Protectant activity of growth hormone against postischemic ventricular dysfunction in hearts from aged rats
38. Identification and characterization of a new growth hormone releasing peptide receptor in the heart
39. Evidence for direct cardiac effects of Hexarelin in the hypophisectomized rat
40. Tissue distribution of GHRP receptors in humans
41. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans
42. Measurement of absolute left ventricular volume from gated blood pool studies
43. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
44. Identification and characterization of a new GHRP receptor in the heart
45. Binding sites for growth hormone-releasing peptide